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cally associated with Pseudomona aeruginosa. It can be a potentially 
fatal systemic infection and can be a manifestation of an underlying 
clinical entity.1-3
We performed a retrospective study of all EG cases from 
2004	to	2010	in	a	university	hospital	in	Monterrey,	Mexico.
CASE REPORT
We report 8 cases that occurred with 5 female patients and 
3	male	patients,	ages	between	4	months	and	2	years.	Four	patients	
were	apparently	previously	healthy	at	admission,	and	the	other	4	
had a degree of immunosuppression (hemophagocytic lymphohis-
tiocytosis,	undifferentiated	embryonic	liver	sarcoma	and	desnutri-
tion	(Table	1)).	All	patients	presented	at	our	institution	in	a	febrile	





up	was	significant	 for	neutrophilia	 in	3	patients,	neutropenia	 in	4	
patients,	 thrombocytopenia	 in	7	patients,	and	thrombocytosis	 in	1	
patient. Bacteria blood cultures from 7 patients grew Pseudomona 
aeruginosa. The patient with negative blood culture showed a posi-




therapy	 (4	 ceftazidime	 and	 amikacin,	 2	 imipenem	 and	 amikacin,	
1	meropenem	and	amikacin,	and	1	meropenem	and	ciprofloxacin)	









previously	 healthy	 patients,	 the	 immunological	 evaluation	 is	 im-
portant	to	rule	out	underlying	immunodeficiencies.2
EG has also been described in association with other patho-
gens including Aeromonas hydrophila,	 Staphylococcus aureus,	 Strep-
tococcus pyogenes,	 Serratia marcescens,	 Klebsiella	 pneumoniae,	 Xan-
An Bras Dermatol. 2017;92(5):698-700.
Table 1: Study of 8 cases with ecthyma gangrenosum
Case Age/Sex Localization
Previously healthy or 
immunocompromised
Laboratory findings Hemoculture Treatment Outcome











































































tion: patient presenting 
with erythema and edema 
on	the	left	cheek.	Lower	
lip showing ulceration 
with	necrotic	tissue;	
(B) day 7 showing new 




freundii,	 Corynebacterium	 diphtheriae,	Neisseria	 gonorrhoeae,	 Yersinia	
pestis,	Candida	albicans,	Aspergillus fumigatus,	Mucormycosis,	Fusari-
um solani,	Scytalidium dimidiatum,	Pseudallescheria boydii,	and	Curvu-
laria species.1-3




Antibiotic	 therapy	with	 spectrum	 for	Pseudomonas aerugi-
nosa	 includes	aminoglycosides,	third-	and	fourth-generation	ceph-
alosporins,	 β-lactam	 antibiotics,	 and	 broad-spectrum	 penicillins.	
In addition to the results of susceptibility tests for the isolate from 
the	patient,	local	patterns	of	susceptibility	for	each	hospital	should	
be considered in the initial choice of treatment. Some studies com-
paring combination therapy with monotherapy reveal that the regi-
mens do not affect mortality rates.5-7
Prognosis depends on the host and on the degree of immu-
nosuppression.4 The disease has a high mortality rate. In patients 
with EG and septicemia secondary to Pseudomonas,	 it	ranges	from	
38%-77%,	 and	 in	 patients	with	 no	 sepsis,	 it	 is	 described	 in	 about	
15%.8 The most important prognostic factor of mortality in invasive 
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forms is the presence of neutropenia at diagnosis.9 Luigi et al. re-
ported that severe sepsis by P. aeuruginosa can occur in previously 
healthy children with a mortality rate of 55%.10
Immunological evaluation is essential in all the patients 
(including	the	apparently	healthy	ones)	as	immunosuppression	can	
drastically change the prognosis. EG in healthy patients has a high 
mortality rate and early diagnosis and aggressive antibiotic treat-
ment is imperative as it can improve the patient’s prognosis. q
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FIgure 2: Progression of ecthyma gangrenosum on the left arm. (A)	Initial	presentation	with	erythematous	nodule;	(B)	increase	in	size	of	
the	area	with	erythema	and	ulceration;	(C) Ulceration with central necrotic crust 
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